In the latest market close, Merck (MRK) reached $88.11, with a +0.27% movement compared to the previous day. The stock exceeded the S&P 500, which registered a loss of 1.12% for the day. Meanwhile, ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

Merck's revenues are driven by cancer med Keytruda, which faces patent expiry by 2028. See why I rate MRK stock a hold.

The general mood among these heavyweight investors is divided, with 63% leaning bullish and 36% bearish. Among these notable ...

For more information, visit www.merck.com and connect with us on X (formerly Twitter ... N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking ...

Merck (MRK) has signed a licensing agreement for a heart disease drug developed by a Chinese company in a deal worth up to $2 billion, the latest in a series of cross-border deals between Western drug ...

NEW YORK, NY / ACCESS Newswire / March 25, 2025 / WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Merck & Co., Inc. (NYSE:MRK) between February 3, 2022 and ...

“Due to significant reductions in demand for these products, the company has decided to cease operations at the plant,” the ...

In the latest market close, Merck (MRK) reached $94.71, with a +1.46% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 0.91%. Meanwhile, the Dow lost 1.5%, and ...